TAKEDA PHARMACEUTIC

Takeda Q1 2026: revenue up 5.4% despite net‑profit dip, driven by yen gain and flagship drugs, while operating margin grows and pipeline strength keeps growth prospects strong.

Takeda raises ¥1.2 trillion to fuel a high‑investment R&D pipeline across oncology, autoimmune, rare disease and neurology, boosting shareholder confidence and market share.